Abstract: A method for the permanent shaping and color modification of keratinic in a single process includes the following steps. First, an aqueous composition, including at least one keratin-reducing compound and at least one alkalizing agent, is applied to the keratinic fibers and is left on the keratinic fibers for a period of 5 to 50 minutes at a temperature of 20 to 45° C. The keratinic fibers are rinsed, and optionally dried. Next, a composition including at least one oxidation dye precursor and at least one oxidizing agent is applied to the keratinic fibers and the keratinic fibers are deformed. That composition is allowed to act for 10 to 35 minutes. An aqueous composition including at least one oxidizing agent, is applied to the keratinic fibers for 30 seconds to 15 minutes. The keratinic fibers are rinsed out, along with removal of the deformation aids.

Abstract: The present invention features compositions comprising a plurality of therapeutic agents wherein the presence of one therapeutic agent enhances the properties of at least one other therapeutic agent. In one embodiment, the therapeutic agents are cystic fibrosis transmembrane conductance regulators (CFTR) such as a CFTR corrector or CFTR potentiator for the treatment of CFTR mediated diseases such as cystic fibrosis. Methods and kits thereof are also disclosed.

Abstract: Compositions having a drug-loaded microparticle and bone cement and methods of making such compositions are disclosed. Also disclosed are methods of employing such compositions for the treatment of injected joint spaces and bone disease.

Abstract: The present invention provides a cationic arabinoxylan and the hydrophobically modified product thereof. The cationic arabinoxylan is prepared based on a cereal arabinoxylan and a quaternizing agent, with water as solvent and strong alkali as catalyst. The hydrophobically modified product is prepared based on cationic arabinoxylan and alkyl halide, with pyridine as catalyst. Said cationic arabinoxylan and the hydrophobically modified product thereof can be used as a conditioning agent or thickener in cosmetics or personal care compositions, and can also be used in textile, papermaking, pharmaceutical and food industry applications.

Abstract: The present invention relates to new classes of monomeric compounds, which may be polymerized to form novel biodegradable and bioresorble polymers and copolymers. These polymers and co-polymers, while not limited thereto, may be adapted for radio-opacity and are useful for medical device applications and controlled release therapeutic formulations.

Abstract: Described herein are polymeric nanoparticles that include a therapeutic agent, and methods of making and using such therapeutic nanoparticles. In some embodiments, the contemplated nanoparticles may include an excipient.

Abstract: The present invention relates to a method of making an amino silicone nanoemulsions. More specifically, the present invention relates to a method of making an amino silicone nanoemulsions that may be used to protect surfaces from being soiled or wetted.

Abstract: The present application provides a dosage form and related methods for making the dosage form. The dosage form generally comprises a hydrophilic active ingredient, a plurality of solid, porous microcarriers, each having a hydrophobic surface, an optional hydrophobic encapsulant, and a hydrophilic delivery agent, wherein (i) the hydrophilic active ingredient is associated with the plurality of solid, porous microcarriers, (ii) the plurality of solid, porous microcarriers is encapsulated by the hydrophobic encapsulant, and (iii) the hydrophilic delivery agent is physically separated from a majority of the hydrophilic active ingredient by a boundary between the hydrophilic delivery agent and the hydrophobic encapsulant. In some embodiments, the dosage form is for topical application. In some additional embodiments, the plurality of solid, porous microcarriers is formed by modifying the microcarriers to increase their hydrophobicity.

Abstract: Non-linear multiblock copolymer-drug conjugates for the treatment and prevention of diseases and disorders of the eye are provided. The polymer-drug conjugates can form nanoparticles, microparticles, and implants that are capable of effectively delivering therapeutic levels of one or more active agents for an extended period of time. Administration to the eye of an active agent in the form of a non-linear multiblock copolymer-drug conjugate produces decreased side effects when compared to administration of the active agent alone. Also provided are methods of treating intraocular neovascular diseases, such as wet age-related macular degeneration as well as diseases and disorders of the eye associated with inflammation, such as uveitis.

Abstract: Polymeric conjugates of a polymeric backbone formed of a plurality of backbone units and having attached to portions of the backbone units two or more therapeutically active agents, or one or more therapeutically active agents and a NCAM targeting moiety, are disclosed. Uses of such polymeric conjugates in treating and/or monitoring cancer and/or medical conditions associated with angiogenesis are also disclosed.

Abstract: An object of the present invention is to provide a composition that serves as an efficient arginine substrate for inducible NO synthase (iNOS) in tumor. The present invention provides a polyion complex (PIC) of PEG-b-poly(L-Arg) or poly(L-Arg)-b-PEG-b-poly(L-Arg) and a polyanionic polymer, and use thereof.

Abstract: The present invention relates to novel compounds of formula (I) to cosmetic compositions comprising same, and also to the use thereof for preventing and/or cosmetically treating the signs of aging of the skin.

Abstract: A novel dietary supplement and nutritional aid and methods for the manufacture and administration of the same are disclosed for the inhibition of OCD in afflicted animals, particularly horses. The present invention relates generally to a feed composition and methods of use thereof for reducing the development of Osteochondrosis Dissecans (OCD) lesions in predisposed young animals, particularly horses. More specifically the invention provides a nutritional formula that targets the metabolic deficiencies identified as being correlated with development of OCD.

Abstract: Provided are cold process formulation aids (CPFAs), methods for their manufacture, and personal care products made using them. CPFAs include (i) a polymer having an aliphatic backbone and a plurality of pendant groups thereon that are pendant ionic or ionizable groups, or pendant groups having at least one permanent dipole that includes an acid, alcohol, thiol, ester, amine, amide, imide, imine, or nitrile moiety, and (ii) a wax selected from natural waxes and synthetic waxes, wherein if the wax is not micronized and is not self-emulsifying, the ratio, by weight, of the non-micronized wax to the polymer having an aliphatic backbone is from about 60:40 to 80:20, and if the wax is a micronized wax or a self-emulsifying wax, the ratio, by weight, of wax to polymer backbone is 70:30 to 98:2.

Abstract: Zwitterionic polymer and mixed charge copolymer bioconjugates, methods for making and using the bioconjugates.

Abstract: The present disclosure relates to fibers implantable in the body of a human or animal and processes for manufacturing such a fiber. The fiber undergoes a reduction in surface area to volume ratio of a factor of 1.05-10 upon injection in the human or animal body. In an embodiment, a process for manufacturing a fiber comprises extruding a biodegradable polymer into a fiber capable of fitting in a syringe needle of at least 25 Gauge, and cooling the fiber below its dry glass transition temperature while the fiber is under tension.

Abstract: Esters of oligo-hydroxycarboxylic acids have the general formula ( ): wherein at least one of the radicals R1, R4 or R5 is a linear or branched aliphatic hydrocarbon radical having 6 to 30 carbon atoms and 0, 1, 2 or 3 double bonds. Cosmetic and pharmaceutical agents contain said esters. These esters are effective as thickeners, in particular for compositions containing surfactants.

Abstract: The present invention relates to a method that includes providing a formulation having an isocyanate-functional prepolymer and a curing component comprising an amino-functional aspartic ester of the general formula (I) applying the formulation to a cell tissue; and curing the formulation such that the loss of blood (haemostatic) or tissue fluids is staunched or leaks in cell tissues are sealed.

Abstract: A method for administering an active agent to a pleura of a patient includes preparing a composition including a foamable liquid and the active agent, incorporating a gas into the foamable liquid to create a foam containing the active agent, introducing the foam into a pleural cavity of the patient defined by the pleura, and contacting the pleura with the foam. A method of pleurodesis includes introducing a composition into a pleural cavity defined by pleurae of a patient, the composition including a foamable liquid and an active agent capable of causing inflammation and/or adhesion of the pleurae. A composition for treating a pleura of a patient includes a liquid component including a biocompatible composition having a viscosity which increases in response to an increase in temperature, and an active agent capable of causing inflammation and/or adhesion of the pleura.

Abstract: The present invention relates to a method for the preparation of polymer shells, preferably composed of cellulose or hemicellulose, comprising the steps of dissolving the polymer component in a first solvent, preferably an organic solvent and precipitating the polymer component by contacting the first solution with a second solvent, which second solvent has a polar character, and in which second solvent the polymer component is essentially insoluble, thereby obtaining polymer shells. Moreover, the invention refers to the polymer shells as such, having permeable and responsive properties, as well as various applications comprising such polymer shells within the fields of drug delivery, separation techniques, and inter alia filling material.